General Information |
| Summary |
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2023-03-24 |
| End date (estimated) |
2029-04-11 |
| Clinical feature |
| Label |
age related macular degeneration |
| Link |
http://purl.obolibrary.org/obo/DOID_10871 |
| Description |
A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.; OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT05626114 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05626114 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05626114 |
| Study sites |
|
| Public contact |
| Email |
global-roche-genentech-trials@gene.com |
| Public email |
global-roche-genentech-trials@gene.com |
| First name |
Clinical Trials Hoffmann-La Roche |
| Phone |
+1 888-662-6728 (U.S. Only) |
|
| Sponsors |
Genentech, Inc.
|
Cells |
| Which differentiated cell type is used |
| Label |
retinal pigment epithelial cell |
| Link |
http://purl.obolibrary.org/obo/CL_0002586 |
| Description |
An epithelial cell of the retinal pigmented epithelium. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
60 |
